News - Financing risk management - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

Company news

CEO of Efung Capital Named to Investors.com's "2026·54 Best Young Investors" List |

Today, Investors.com officially released its "Investors.com 2026·54 Best Young Investors List". Mr. Pai Zhu, CEO of Efung Capital, stood out among numerous competitors and was named to the prestigious list, thanks to his profound industry insights and continuous deep cultivation in the biopharmaceutical field.This list is initiated by Investors.com in collaboration with the Investors Research Institute. It aims to recognize a new generation of investors who possess a unique combination of technological acumen, industrial insight, and innovative action during this critical period of structural reshaping in the equity investment industry.Entering 2026, the industry's logic is shifting from "scale expansion" to "quality enhancement," with VC/PE firms focusing more intensively on specialized and sophisticated sectors that drive niche innovation. Against this backdrop, young investors, through their rapid adoption of new techno...

2026 - 04 - 30
Monthly Health Reader | April 2026

On April 28, the Political Bureau of the CPC Central Committee held a meeting to analyze the economic situation and deploy work priorities. The meeting emphasized the need to implement, with precision and effectiveness, a more proactive fiscal policy and a moderately accommodative monetary policy, to boost domestic demand and drive industrial upgrading, and to strive for a good start to the 15th Five-Year Plan period. This has sent a clear signal to the market: capital will be directed toward technological innovation fields aligned with national strategies, particularly "hard tech" domains that can propel industrial transformation.As one of China's earliest professional investment institutions focusing on the biomedicine and high-end medical device sectors, Yifeng Capital has long adhered to the strategy of "investing early, in small-sized enterprises, and in hard tech," moving in sync with the national agenda. This month, several of Yifeng Capital's portfol...

2026 - 04 - 30
Shensi Bio's Ultra-Long-Acting Recombinant Factor VIII FRSW117 NMPA Application Accepted

Shensi Bio announced today (April 29, 2026) that its independently developed Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (project code: FRSW117) has been submitted for marketing authorization to the National Medical Products Administration (NMPA) and has officially been accepted for review. FRSW117 is a world-first, ultra-long-acting recombinant Factor VIII product that combines two half-life extension technologies—Fc fusion and PEGylation. It is intended for routine prophylactic treatment, on-demand replacement therapy, and perioperative bleeding management in patients with hemophilia A, with a dosing frequency of once weekly for routine prophylaxis.Hemophilia A is an X-linked recessive inherited bleeding disorder caused by a deficiency of coagulation Factor VIII, characterized by delayed, persistent, and slow bleeding. According to hemophilia prevalence survey data in China, hemophilia A accounts for approximately 80% to 85% of all hemophilia c...

2026 - 04 - 29
Ef Capital CEO Zhu Pai Receives the "2026 Top 40 Under 40 Best Direct Investment Fund Young Investor

Today, the FOF Research Center officially released its "2026 40U40 Outstanding Young Investors" rankings. Zhu Pai, CEO of Ef Capital, has been honored with the "2026 Top 40 Under 40 (40U40) Best Direct Investment Fund Young Investor" award.On the occasion of the upcoming Youth Day (May 4th), the FOF Research Center, supported by comprehensive data and in-depth research analysis, unveiled this significant ranking designed to encourage dedicated young professionals who quietly contribute to the private equity investment industry. Industry consensus traditionally holds that talent in investment follows a pyramid structure—the older, the more senior. However, with the full arrival of the digital and hard-tech era, on highly specialized tracks such as deep tech and biomedicine, a group of outstanding Chinese young investors are leveraging their solid expertise and precise forward-looking vision to identify investment targets with truly long-term value.In this selection, ...

2026 - 04 - 28
Highlands Pharma Reports Positive Phase III Data for RA Drug Ginositinib (TLL-018)

Highlands Pharmaceuticals today announced positive topline results from its Phase III clinical trial ("TARA Study") evaluating Ginositinib, an oral small-molecule JAK1/TYK2 inhibitor， for the treatment of active rheumatoid arthritis (RA). The study met its primary and all secondary efficacy endpoints, demonstrating statistically superior outcomes compared to the positive control drug Tofacitinib (Xeljanz), along with a favorable safety and tolerability profile. This marks the first registrational study globally to use another JAK inhibitor as a positive control and achieve superior efficacy results.The TARA Study is a multicenter, randomized, double-blind Phase III trial evaluating the efficacy and safety of Ginositinib in RA patients with inadequate response or intolerance to biologic agents. A total of 459 subjects were enrolled and randomized to receive either Ginositinib or the control drug Tofacitinib for 52 consecutive weeks. The primary efficacy endpoint was the ACR50 ...

2026 - 04 - 27
EFUNG Capital Secures Multiple Annual Honors at the ChinaVenture Awards

Today, at the highly anticipated "ChinaVenture 20th Annual Investment Summit · Annual Conference," the prestigious ChinaVenture Awards list was officially unveiled. Leveraging its deep expertise in the healthcare industry, EFUNG Capital swept multiple significant institutional and individual awards.EFUNG Capital was honored with: ChinaVenture 2025 Top 50 Best RMB-denominated Venture Capital Firms, ChinaVenture 2025 Top 20 Medical Device Investment Institutions in the Healthcare Sector, and ChinaVenture 2025 Top 100 Best Venture Capital Firms.At the same time, Mr. Zhu Pai, CEO of EFUNG Capital, stood out among the new generation of investors and was awarded: ChinaVenture 2025 NOVA Rising Star Investor Top 50.Portfolio companies within the EFUNG Capital ecosystem also delivered outstanding performances. Core Medical and Nurotron successfully made the list: ChinaVenture 2025 Top 10 Medical Device Investment Cases in the Healthcare Sector.The ChinaVenture Awards are an autho...

2026 - 04 - 24

Copyright © 2018 2021.All Rights Reserved 粤公网安备44030402002338号 Rhino Cloud provides enterprise cloud services 犀牛云提供云计算服务